{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:02:38Z","timestamp":1792620158667,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jaad.2023.03.035","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T01:55:03Z","timestamp":1680486903000},"page":"274-282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Malignancy rates through 5\u00a0years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0084-3131","authenticated-orcid":false,"given":"Andrew","family":"Blauvelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u04abi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2023.03.035_bib1","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jamadermatol.2015.4847","article-title":"The risk of cancer in patients with psoriasis: a population-based cohort study in the Health Improvement Network","volume":"152","author":"Chiesa Fuxench","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2023.03.035_bib2","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/sj.jid.5700410","article-title":"The risk of lymphoma in patients with psoriasis","volume":"126","author":"Gelfand","year":"2006","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.03.035_bib3","first-page":"180","article-title":"Increased prevalence of cancer in adult patients with psoriasis in the United States: A claims based analysis","volume":"17","author":"Kimball","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2023.03.035_bib4","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamadermatol.2019.3056","article-title":"Association of psoriasis with the risk of developing or dying of cancer: A systematic review and meta-analysis","volume":"155","author":"Trafford","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.03.035_bib5","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jaad.2017.07.013","article-title":"Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry","volume":"77","author":"Fiorentino","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.03.035_bib6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/09546634.2011.652064","article-title":"An evidence-based review of skin cancer rates on biologic therapies","volume":"23","author":"Kamangar","year":"2012","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2023.03.035_bib7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cyto.2016.09.013","article-title":"Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?","volume":"101","author":"Chen","year":"2018","journal-title":"Cytokine"},{"issue":"suppl 3","key":"10.1016\/j.jaad.2023.03.035_bib8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jdv.12165","article-title":"Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies","volume":"27","author":"Pouplard","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.jaad.2023.03.035_bib9","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/jid.2009.113","article-title":"Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis","volume":"129","author":"Brauchli","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.03.035_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjd.15830","article-title":"Risk of cancer in patients with psoriasis on biological therapies: a systematic review","volume":"178","author":"Peleva","year":"2018","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.03.035_bib11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: A comprehensive review","volume":"22","author":"Yang","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2023.03.035_bib12","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/jdv.14868","article-title":"Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders","volume":"32","author":"Gooderham","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2023.03.035_bib13","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaad.2021.11.004","article-title":"Consistent safety profile with up to 5 years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.03.035_bib14","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/bjd.20568","article-title":"Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2","volume":"185","author":"Reich","year":"2021","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.03.035_bib15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.03.035_bib16","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2023.03.035_bib17","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"14","author":"Papp","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2023.03.035_bib18","doi-asserted-by":"crossref","unstructured":"Lebwohl MG, Merola JF, Rowland K, et al. Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with greater than 8600 patient-years of exposure. Br J Dermatol. Published online April 6, 2023. https:\/\/doi.org\/10.1093\/bjd\/ljad115.","DOI":"10.1093\/bjd\/ljad115"},{"key":"10.1016\/j.jaad.2023.03.035_bib20","doi-asserted-by":"crossref","unstructured":"Blauvelt A, Tha\u00e7i D, Papp KA, et\u00a0al. Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials. Br J Dermatol. Published online March 22, 2023. https:\/\/doi.org\/10.1093\/bjd\/ljad081","DOI":"10.1093\/bjd\/ljad081"},{"issue":"10","key":"10.1016\/j.jaad.2023.03.035_bib21","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","article-title":"Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012","volume":"151","author":"Rogers","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.03.035_bib22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jaad.2016.08.019","article-title":"Incidence ratio of basal cell carcinoma to squamous cell carcinoma equalizes with age","volume":"76","author":"Chahal","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.03.035_bib23","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1159\/000510685","article-title":"Skin cancer development in solid organ transplant recipients in Switzerland (Swiss Transplant Cohort Study)","volume":"237","author":"Stenz","year":"2021","journal-title":"Dermatology"},{"issue":"2","key":"10.1016\/j.jaad.2023.03.035_bib24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jaad.2010.11.062","article-title":"Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients","volume":"65","author":"O\u2019Reilly Zwald","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.03.035_bib25","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bjd.20136","article-title":"The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up","volume":"185","author":"Lebwohl","year":"2021","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.03.035_bib26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s13555-019-00340-3","article-title":"Safety of ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure","volume":"10","author":"Armstrong","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7","key":"10.1016\/j.jaad.2023.03.035_bib27","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamadermatol.2022.1185","article-title":"Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from phase 2 and phase 3 randomized clinical trials","volume":"158","author":"Gordon","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.03.035_bib28","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.03.035_bib29","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjd.20818","article-title":"Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis","volume":"186","author":"Gordon","year":"2022","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.03.035_bib30","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjd.18232","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"issue":"7101","key":"10.1016\/j.jaad.2023.03.035_bib31","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature04808","article-title":"IL-23 promotes tumour incidence and growth","volume":"442","author":"Langowski","year":"2006","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jaad.2023.03.035_bib32","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.bbrc.2016.12.048","article-title":"Tumor-promoting effect of IL-23 in mammary cancer mediated by infiltration of M2 macrophages and neutrophils in tumor microenvironment","volume":"482","author":"Nie","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.jaad.2023.03.035_bib33","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/mi.2013.101","article-title":"Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells","volume":"7","author":"Chan","year":"2014","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jaad.2023.03.035_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-3-030-55617-4_6","article-title":"IL-23 and the tumor microenvironment","volume":"1290","author":"Subhadarshani","year":"2021","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"10.1016\/j.jaad.2023.03.035_bib35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.it.2007.03.006","article-title":"Swords into plowshares: IL-23 repurposes tumor immune surveillance","volume":"28","author":"Langowski","year":"2007","journal-title":"Trends Immunol"},{"issue":"9","key":"10.1016\/j.jaad.2023.03.035_bib36","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.7326\/M22-1460","article-title":"Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update","volume":"175","author":"DeTora","year":"2022","journal-title":"Ann Intern Med"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223005248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223005248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:22:50Z","timestamp":1759274570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223005248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0190962223005248"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.03.035","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignancy rates through 5\u00a0years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.03.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}